As of April 18, 2025, Affimed (AFMD) has a market cap of $12.024 million USD. According to our data, Affimed is ranked No.8746 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 18, 2025 | $12.02 M |
-38.36%
|
Dec 31, 2024 | $19.51 M |
-80.96%
|
Dec 29, 2023 | $0.10 B |
-49.60%
|
Dec 30, 2022 | $0.20 B |
-77.54%
|
Dec 31, 2021 | $0.90 B |
-5.15%
|
Dec 31, 2020 | $0.95 B |
112.41%
|
Dec 31, 2019 | $0.45 B |
-11.90%
|
Dec 31, 2018 | $0.51 B |
139.23%
|
Dec 29, 2017 | $0.21 B |
-27.78%
|
Dec 30, 2016 | $0.30 B |
-74.72%
|
Dec 31, 2015 | $1.17 B |
14.84%
|
Dec 31, 2014 | $1.02 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Genmab
GMAB
|
$12.54 B |
-0.000 M
|
![]() Denmark
|
![]() MacroGenics
MGNX
|
$79.49 M |
-0.000 M
|
![]() USA
|
![]() Xencor
XNCR
|
$0.68 B |
-0.000 M
|
![]() USA
|
![]() Zymeworks
ZYME
|
$0.80 B |
-0.000 M
|
![]() Canada
|
![]() Adaptimmune Therapeutics
ADAP
|
$61.27 M |
0.051 M
|
![]() UK
|
![]() Iovance Biotherapeutics
IOVA
|
$1.00 B |
-0.000 M
|
![]() USA
|
![]() Fate Therapeutics
FATE
|
$0.13 B |
0.000 M
|
![]() USA
|
![]() Allogene Therapeutics
ALLO
|
$0.32 B |
-0.000 M
|
![]() USA
|
![]() Atara Biotherapeutics
ATRA
|
$36.15 M |
0.000 M
|
![]() USA
|
![]() Autolus Therapeutics
AUTL
|
$0.38 B |
0.000 M
|
![]() UK
|
![]() Cellectis
CLLS
|
$0.20 B |
49.857 M
|
![]() France
|
![]() CRISPR Therapeutics
CRSP
|
$3.26 B |
0.000 M
|
![]() Switzerland
|
![]() Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
![]() USA
|
![]() Intellia Therapeutics
NTLA
|
$0.75 B |
-0.000 M
|
![]() USA
|
Market Cap | = | AFMD Stock Price | * | AFMD Shares Outstanding |
= | $0.73 | * | 16.39 M | |
= | $12.02 M |